GSK taps Angiochem to take enzymes across blood-brain barrier
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is stepping up its activity in the rare disease area, signing an early-stage deal that may yield a breakthrough in treatments for lysosomal storage disorders (LSDs). It is offering Angiochem of Canada upwards of $300 million if it can help it develop blood-brain barrier (BBB)-crossing enzyme replacement therapies which could for the first time address the CNS symptoms of such diseases. The deal will see Angiochem, which specialises in getting drugs through the BBB, bring at least one product up to the point of IND notification for GSK's rare diseases unit to take on for clinical development and commercialisation.